Genaera Presents Preclinical Data On Trodusquemine (msi-1436) For The Treatment Of Obesity At The American Diabetes Association 67th Scientific Session
- Category: Small Molecules
- Published on Tuesday, 26 June 2007 04:00
- Hits: 1339
PLYMOUTH MEETING, PA, USA | June 25, 2007 | Genaera Corporation (NASDAQ: GENR) today announced that data from a preclinical study of trodusquemine (MSI-1436) for the treatment of obesity were presented during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz, Genaera research scientist and lead author of Abstract #1801-P, presented, “Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels.”
The poster presentation summarizes results from preclinical studies demonstrating that trodusquemine suppresses appetite and causes differential weight loss in a mouse model of dietinduced obesity (DIO). Data presented also indicates that trodusquemine selectively inhibits PTP-1B, an enzyme central to controlling the function of both the leptin and insulin pathways. In addition, trodusquemine was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model, making trodusquemine a promising therapeutic candidate.
“This preclinical data supports our current Phase 1 clinical strategy for trodusquemine as a treatment for obesity and further reinforces our belief that trodusquemine may also be successful in the treatment of type 2 diabetes,” stated Jack Armstrong, President and Chief Executive Officer of Genaera. “We believe that, if successful, trodusquemine could be an effective monotherapy able to treat both obesity and type 2 diabetes, and could revolutionize the way these metabolic diseases are treated.”
Scientists from Genaera will be available for discussion of the poster today from 12:00 p.m. to 2:00 p.m. Central Time in the Poster Hall at the conference. For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&MenuID=100
About Trodusquemine (MSI-1436)
Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established, validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B), that is central to both insulin and leptin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment of two of the most serious metabolic diseases, obesity and type 2 diabetes. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to address co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquamine (or MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune for a second core program that is presently undergoing Phase 2 clinical testing. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.